Hormone Replacement Therapy (HRT) Shortages in the UK
As HRT shortages continue to impact patients in the UK, we wanted to provide the most recent information regarding the availability of the Evorel (estradiol) range of HRT products.
In October 2019, the Janssen Pharmaceutical Companies of Johnson & Johnson entered into an asset purchase agreement for its Evorel range of products (Systen/Evorel/Evopad patches, including the Conti and Sequi presentations) with Theramex HQ UK Limited.
Theramex has a well-established history in women’s health and we believe this agreement will help ensure the long-term availability of these products for the patients who use them. We want to emphasise that the agreement with Theramex was not the cause or the reason for the shortages of the Evorel range.
Theramex has been working with suppliers to shorten the manufacturing timelines, and accelerate supply to bring the product back to market earlier than originally planned.
For the latest information on supply of the Evorel range of products, or any enquiries regarding availability please contact the Theramex team at [email protected] or +44 (0)333 009 6795.
For patients with questions regarding current or alternative HRT therapies during this time, we advise speaking to your GP or healthcare professional.
If your enquiry is related to an adverse event associated with a Janssen product, please contact our Drug Safety Department on 01494 567447 or by e-mail at: [email protected].
The Janssen UK team
Job Code: CP-151265 Date of preparation: April 2020